Mesenchymal stromal (stem) cells to improve solid organ transplant outcome: Lessons from the initial clinical trials

Antonello Pileggi, Xiumin Xu, Jianming Tan, Camillo Ricordi

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Purpose of review: Discuss the recent progress on the clinical use of mesenchymal stromal (stem) cells (MSC) in solid organ transplantation (SOT). Recent findings: Tissue repair and immunomodulatory properties have been recognized for MSC obtained from different human tissues. MSC-based therapy has been proposed to reduce ischemia-reperfusion injury and to promote immune tolerance. The results of recent clinical trial support the safety and promising effects of autologous and allogeneic MSC in SOT. Collectively, the use of MSC in recipients of living donor kidney transplantation was associated with improved graft function, reduced rejection, ability to omit induction and/or lower maintenance immunosuppression regimen, as well as to treat rejection episodes. Summary: We are living in very exciting times with the implementation of novel clinical trials aimed at establishing safety, feasibility and efficacy of cellular therapies including MSC to improve SOT outcomes. The results of the initial clinical trials support the safety of MSC-based therapy and justifying cautious optimism for the immediate future.

Original languageEnglish
Pages (from-to)672-681
Number of pages10
JournalCurrent Opinion in Organ Transplantation
Volume18
Issue number6
DOIs
StatePublished - Dec 1 2013

Fingerprint

Organ Transplantation
Mesenchymal Stromal Cells
Clinical Trials
Transplants
Safety
Immune Tolerance
Aptitude
Living Donors
Reperfusion Injury
Kidney Transplantation
Immunosuppression
Therapeutics
Maintenance
Rejection (Psychology)

Keywords

  • Acute cellular rejection
  • Adipose tissue
  • Bone marrow
  • Clinical trial
  • Immunosuppression
  • Ischemia/reperfusion injury
  • Living-donor kidney transplantation
  • Mesenchymal stem cells
  • Opportunistic infections
  • Solid organ transplantation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation

Cite this

Mesenchymal stromal (stem) cells to improve solid organ transplant outcome : Lessons from the initial clinical trials. / Pileggi, Antonello; Xu, Xiumin; Tan, Jianming; Ricordi, Camillo.

In: Current Opinion in Organ Transplantation, Vol. 18, No. 6, 01.12.2013, p. 672-681.

Research output: Contribution to journalArticle

@article{b76b2a888e6142e8b2de0577dce56949,
title = "Mesenchymal stromal (stem) cells to improve solid organ transplant outcome: Lessons from the initial clinical trials",
abstract = "Purpose of review: Discuss the recent progress on the clinical use of mesenchymal stromal (stem) cells (MSC) in solid organ transplantation (SOT). Recent findings: Tissue repair and immunomodulatory properties have been recognized for MSC obtained from different human tissues. MSC-based therapy has been proposed to reduce ischemia-reperfusion injury and to promote immune tolerance. The results of recent clinical trial support the safety and promising effects of autologous and allogeneic MSC in SOT. Collectively, the use of MSC in recipients of living donor kidney transplantation was associated with improved graft function, reduced rejection, ability to omit induction and/or lower maintenance immunosuppression regimen, as well as to treat rejection episodes. Summary: We are living in very exciting times with the implementation of novel clinical trials aimed at establishing safety, feasibility and efficacy of cellular therapies including MSC to improve SOT outcomes. The results of the initial clinical trials support the safety of MSC-based therapy and justifying cautious optimism for the immediate future.",
keywords = "Acute cellular rejection, Adipose tissue, Bone marrow, Clinical trial, Immunosuppression, Ischemia/reperfusion injury, Living-donor kidney transplantation, Mesenchymal stem cells, Opportunistic infections, Solid organ transplantation",
author = "Antonello Pileggi and Xiumin Xu and Jianming Tan and Camillo Ricordi",
year = "2013",
month = "12",
day = "1",
doi = "10.1097/MOT.0000000000000029",
language = "English",
volume = "18",
pages = "672--681",
journal = "Current Opinion in Organ Transplantation",
issn = "1087-2418",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Mesenchymal stromal (stem) cells to improve solid organ transplant outcome

T2 - Lessons from the initial clinical trials

AU - Pileggi, Antonello

AU - Xu, Xiumin

AU - Tan, Jianming

AU - Ricordi, Camillo

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Purpose of review: Discuss the recent progress on the clinical use of mesenchymal stromal (stem) cells (MSC) in solid organ transplantation (SOT). Recent findings: Tissue repair and immunomodulatory properties have been recognized for MSC obtained from different human tissues. MSC-based therapy has been proposed to reduce ischemia-reperfusion injury and to promote immune tolerance. The results of recent clinical trial support the safety and promising effects of autologous and allogeneic MSC in SOT. Collectively, the use of MSC in recipients of living donor kidney transplantation was associated with improved graft function, reduced rejection, ability to omit induction and/or lower maintenance immunosuppression regimen, as well as to treat rejection episodes. Summary: We are living in very exciting times with the implementation of novel clinical trials aimed at establishing safety, feasibility and efficacy of cellular therapies including MSC to improve SOT outcomes. The results of the initial clinical trials support the safety of MSC-based therapy and justifying cautious optimism for the immediate future.

AB - Purpose of review: Discuss the recent progress on the clinical use of mesenchymal stromal (stem) cells (MSC) in solid organ transplantation (SOT). Recent findings: Tissue repair and immunomodulatory properties have been recognized for MSC obtained from different human tissues. MSC-based therapy has been proposed to reduce ischemia-reperfusion injury and to promote immune tolerance. The results of recent clinical trial support the safety and promising effects of autologous and allogeneic MSC in SOT. Collectively, the use of MSC in recipients of living donor kidney transplantation was associated with improved graft function, reduced rejection, ability to omit induction and/or lower maintenance immunosuppression regimen, as well as to treat rejection episodes. Summary: We are living in very exciting times with the implementation of novel clinical trials aimed at establishing safety, feasibility and efficacy of cellular therapies including MSC to improve SOT outcomes. The results of the initial clinical trials support the safety of MSC-based therapy and justifying cautious optimism for the immediate future.

KW - Acute cellular rejection

KW - Adipose tissue

KW - Bone marrow

KW - Clinical trial

KW - Immunosuppression

KW - Ischemia/reperfusion injury

KW - Living-donor kidney transplantation

KW - Mesenchymal stem cells

KW - Opportunistic infections

KW - Solid organ transplantation

UR - http://www.scopus.com/inward/record.url?scp=84888286540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888286540&partnerID=8YFLogxK

U2 - 10.1097/MOT.0000000000000029

DO - 10.1097/MOT.0000000000000029

M3 - Article

C2 - 24220050

AN - SCOPUS:84888286540

VL - 18

SP - 672

EP - 681

JO - Current Opinion in Organ Transplantation

JF - Current Opinion in Organ Transplantation

SN - 1087-2418

IS - 6

ER -